Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A. Holstein, Philip L. McCarthy, Vera J. Suman et al.|Transplantation and Cellular Therapy|2020Cited by 6
A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)Kalyan Nadiminti, Yogesh Jethava, Christopher Strouse et al.|Blood|2018Cited by 5
Impact of Chemotherapy Based Induction Using Dexamethasone, Cisplatin, Doxorubicin, Cyclophosphamide and Etoposide (DPACE) Versus Novel Agent Induction in Patients Undergoing Tandem Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)Kalyan Nadiminti, Yogesh Jethava, Lindsay Dozeman et al.|Transplantation and Cellular Therapy|2019Cited by 3
A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome predictionKalyan Nadiminti, Sarah L. Mott, Kimberly J. Langer et al.|Blood Cancer Journal|2021Cited by 2
Utility of Bronchoscopy and Bronchoalveolar Lavage (BAL) in the Management of Post-Stem Cell Transplant Pulmonary Complications in 101 to 1000 Days of TransplantRafiullah Rafiullah, Thomas Groß, Aaron Vose et al.|Transplantation and Cellular Therapy|2018Cited by 2